1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC

• DOI: 10.1016/j.annonc.2020.08.1610
• Publication Date: 2020-09-22T05:02:31Z
• Authors: S.S. Schalm; T. Dineen; S.M. Lim; C-W. Park; J. Hsieh; R. Woessner; Z. Zhang; K. Wilson; M. Eno; D. Wilson; B. Williams; J. Campbell; C. De Savi; F. Stevison; C. Utt; T. Guzi; M. Dorsch; K. Hoeflich; B.C. Chul Cho
• Keywords: T790M; Osimertinib